Advances in the management of higher-risk myelodysplastic syndromes: future prospects
Higher-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders wh
Myelodysplastic Syndromes (MDS)
Understanding Secondary AML: High-Risk MDS to AML
Topic(s)
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presenter(s)
Nathan Punwani, MD, MPH
In this webinar, Dr. Nathan Punwani discusses the development of secondary AML from high risk MDS, treatment options and the quality of life impact for patients.
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
Purpose of review: Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dr
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
Introduction: Azacitidine Azacitidine: It works by reducing the amount of methylation in the body.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
Mutations in UBA1, which are disease-defining for VEXAS syndrome, have been reported in patients diagnosed with myelodysplastic syndromes myelody
T-cell dysfunctions in myelodysplastic syndromes
Escape from immune surveillance is a hallmark of cancer. Immune deregulation caused by intrinsic and extrinsic cellular factors, such as altered T-cell functions, leads to immune exhaustion, loss of immune surveillance, and clonal proliferation of tumoral cells. The T-cell immune system contributes to the pathogenesis, maintenance, and progression of myelodysplastic syndrome (MDS).
Kristen Schratz, MD
Institution
Johns Hopkins University
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Pediatric
Yasmin Abaza, MD
Institution
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Stephen Chung, MD
Institution
UT Southwestern Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Stephen Chung, M.D., is an Assistant Professor in the Department of Internal Medicine and the Children’s Research Institute at UT Southwestern Medical Center. He specializes in the care of patients with the myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr. Chung earned his medical degree at Washington University School of Medicine in St. Louis. He completed a residency in internal medicine at Massachusetts General Hospital followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), where he remained as a faculty member of the Leukemia